Sirtuin 6—A Key Regulator of Hepatic Lipid Metabolism and Liver Health
Cells · 19.02.2023 · 12 (4) · 663
DOI: 10.3390/cells12040663 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 19.02.2023. Verfasst von X Charlie Dong. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA. Hauptthemen laut MEDLINE: Lipid Metabolism, Sirtuins, Liver. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Heart Lung and Blood Institute, NIAAA NIH HHS.
Abstract (Originalsprache)
Sirtuin 6 (SIRT6) is an NAD-dependent deacetylase/deacylase/mono-ADP ribosyltransferase, a member of the sirtuin protein family. SIRT6 has been implicated in hepatic lipid homeostasis and liver health. Hepatic lipogenesis is driven by several master regulators including liver X receptor (LXR), carbohydrate response element binding protein (ChREBP), and sterol regulatory element binding protein 1 (SREBP1). Interestingly, these three transcription factors can be negatively regulated by SIRT6 through direct deacetylation. Fatty acid oxidation is regulated by peroxisome proliferator activated receptor alpha (PPARα) in the liver. SIRT6 can promote fatty acid oxidation by the activation of PPARα or the suppression of miR-122. SIRT6 can also directly modulate acyl-CoA synthetase long chain family member 5 (ACSL5) activity for fatty acid oxidation. SIRT6 also plays a critical role in the regulation of total cholesterol and low-density lipoprotein (LDL)-cholesterol through the regulation of SREBP2 and proprotein convertase subtilisin/kexin type 9 (PCSK9), respectively. Hepatic deficiency of Sirt6 in mice has been shown to cause hepatic steatosis, inflammation, and fibrosis, hallmarks of alcoholic and nonalcoholic steatohepatitis. SIRT6 can dampen hepatic inflammation through the modulation of macrophage polarization from M1 to M2 type. Hepatic stellate cells are a key cell type in hepatic fibrogenesis. SIRT6 plays a strong anti-fibrosis role by the suppression of multiple fibrogenic pathways including the transforming growth factor beta (TGFβ)-SMAD family proteins and Hippo pathways. The role of SIRT6 in liver cancer is quite complicated, as both tumor-suppressive and tumor-promoting activities have been documented in the literature. Overall, SIRT6 has multiple salutary effects on metabolic homeostasis and liver health, and it may serve as a therapeutic target for hepatic metabolic diseases. To date, numerous activators and inhibitors of SIRT6 have been developed for translational research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
- Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Förderung
- NIDDK NIH HHS
- National Heart Lung and Blood Institute
- NIAAA NIH HHS
- NIA NIH HHS
- NHLBI NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute on Alcohol Abuse and Alcoholism
- National Institute on Aging
Zitieren
APA
Dong, X. C. (2023). Sirtuin 6—A Key Regulator of Hepatic Lipid Metabolism and Liver Health. Cells, 12(4), 663. https://doi.org/10.3390/cells12040663
Vancouver
Dong XC. Sirtuin 6—A Key Regulator of Hepatic Lipid Metabolism and Liver Health. Cells. 2023;12(4):663. doi:10.3390/cells12040663
BibTeX
@article{Dong2023,
author = {Dong, X Charlie},
title = {Sirtuin 6—A Key Regulator of Hepatic Lipid Metabolism and Liver Health},
journal = {Cells},
year = {2023},
volume = {12},
number = {4},
pages = {663},
doi = {10.3390/cells12040663}
}
EUVIMED